Swiss-German radiopharmaceutical firm Nuclidium raised $98 million in a Series B round led by Kurma Growth Opportunities Fund and other investors. The funding supports clinical development and expansion of copper-61/67 isotope-based radiotheranostic cancer treatments that could outperform current radiotheranostics. Nuclidium’s approach integrates into existing hospital workflows, addressing production bottlenecks in radiopharmaceutical manufacturing. CEO Leila Jaafar highlighted the strategic, long-term investment syndicate bringing expertise across clinical and production domains.